AI in Drug Discovery: Biology Complexity Remains a Major Challenge
zakkohane · x · 2026-08-17
The article counters Dario Amodei's optimistic prediction that AI will cure all diseases soon. Citing research by David Shaywitz and Andreas Bender, it notes that while AI offers significant opportunities in drug R&D, specific areas remain challenged by biological complexity. The piece emphasizes shifting from abstract hype to a realistic assessment of AI's boundaries, highlighting that AI excels when there is sufficient data, clear objectives, and fast feedback, but is not a silver bullet for all biological problems.
More from AGI Musings
- Dev argues AI is great at assets and code but bad at designing game mechanics that feel good — rms80 · 2026-10-03
- CAS Five-Year Plan gives AI for Science its own chapter, setting up a US-vs-China metascience bet — teortaxesTex · 2026-10-03
- Draft standard for autonomous labs emerges as AI-driven science heats up — Afinetheorem · 2026-10-03
- After a diagnosis, use LLMs as agents to dissect pathology, treatments and trials — louisvarge · 2026-10-03
- Blogger defends AI-generated adult content: harms no one, labels optional — JHochderffer · 2026-10-03
- PowerShell creator Jeffrey Snover: AI inference costs collapsed, would short frontier models — dfinke · 2026-10-03